Dokl Biochem Biophys, 2024, 516(1):53-57

Antigenic Peptide-Thioredoxin Fusion Chimeras for In Vitro Stimulus of CD4+ TCR+ Jurkat T Cells

Study of CD4 T cell response and T cell receptor (TCR) specificity is crucial for understanding etiology of immune-mediated diseases and developing targeted therapies. However, solubility, accessibility, and stability of synthetic antigenic peptides used in T cell assays may be a critical point in such studies. Here we present a T cell activation reporter system using recombinant proteins containing antigenic epitopes fused with bacterial thioredoxin (trx-peptides) and obtained by bacterial expression. We report that co-incubation of CD4 HA1.7 TCR reporter Jurkat 76 TRP cells with CD80 HLA-DRB1*01:01 HeLa cells or CD4 Ob.1A12 TCR Jurkat 76 TRP with CD80 HLA-DRB1*15:01 HeLa cells resulted in activation of reporter Jurkat 76 TPR after addition of recombinant trx-peptide fusion proteins, containing TCR-specific epitopes. Trx-peptides were comparable with corresponding synthetic peptides in their capacity to activate Jurkat 76 TPR. These data demonstrate that thioredoxin as a carrier protein (trx) for antigenic peptides exhibits minimal interference with recognition of MHC-specific peptides by TCRs and consequent T cell activation. Our findings highlight potential feasibility of trx-peptides as a reagent for assessing the immunogenicity of antigenic fragments.

IBCH: 11285
Ссылка на статью в журнале: https://link.springer.com/10.1134/S1607672924600210
Нет данных о цитировании
Данные статьи проверены модераторами 2024-09-21

Список научных проектов, где отмечена публикация

  1. Серология рака XXI века: от анализа ландшафта инфильтрирующих в опухоль В-клеточных клонов до адоптивной иммунотерапии. (6 Января 2023 года — 31 Декабря 2025 года). Габибов А.Г.. Грант, РНФ.